公开(公告)号：US20240228616A1

公开(公告)日：2024-07-11

申请号：US18051850

申请日：2022-11-01

Applicant: BioNTech AG ,  Astellas Pharma Inc. ,  TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Türeci ,  Christiane Stadler ,  Julia Holland ,  Hayat Bähr-Mahmud ,  Tim Beissert ,  Laura Kring ,  Fabrice Le Gall ,  Arne Jendretzki ,  Markus Fiedler

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30

CPC classification number: C07K16/2809 ,  C07K16/28 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74

Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefore for treating cancer.

公开(公告)号：US20200062853A1

公开(公告)日：2020-02-27

申请号：US16316534

申请日：2017-07-14

Applicant: GENMAB A/S ,  BIONTECH AG

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  G01N33/569 ,  A61K39/395

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US10188712B2

公开(公告)日：2019-01-29

申请号：US14908246

申请日：2014-07-30

Applicant: BioNTech AG ,  Tron—Translationale Onkologie An der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Petra Simon ,  Christoph Hartmann ,  Stefanie Hubich ,  Thomas Bukur ,  Thorsten Litzenberger

IPC: A61K39/00 ,  C07K14/47 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

公开(公告)号：US20180318436A1

公开(公告)日：2018-11-08

申请号：US15763601

申请日：2016-10-20

Applicant: BIONTECH AG

Inventor： Steve PASCOLO

IPC: A61K47/64 ,  A61P37/04 ,  A61K9/51 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K47/6455 ,  A61K9/513 ,  A61K39/001141 ,  A61K2039/545 ,  A61K2039/55555 ,  A61P35/00 ,  A61P37/04

Abstract: The present invention relates to a method for inducing an immune response manifested by type I interferon production in a synergistic manner comprising the sequential administration of danger signals within a certain timeframe and means for practicing the method. The present invention is particularly useful for immunomodulation, immunotherapy and vaccination.

公开(公告)号：US20180169236A1

公开(公告)日：2018-06-21

申请号：US15675148

申请日：2017-08-11

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schluter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/28 ,  A61K45/06

Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

公开(公告)号：US09944708B2

公开(公告)日：2018-04-17

申请号：US14553669

申请日：2014-11-25

Applicant: BioNTech AG

Inventor： Klaus Pfizenmaier ,  Harald Wajant ,  Dieter Moosmayer ,  Thomas Wuest

IPC: C07K19/00 ,  A61K47/42 ,  A61K38/19 ,  C07K16/28 ,  B82Y5/00 ,  C07K14/525 ,  C07K14/705 ,  A61K47/68 ,  C07K16/30 ,  C07K14/715 ,  C07K7/04 ,  C07K7/06 ,  C07K7/08

CPC classification number: C07K16/2866 ,  A61K47/6899 ,  B82Y5/00 ,  C07K14/525 ,  C07K14/70575 ,  C07K2319/00

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

公开(公告)号：US20160272711A1

公开(公告)日：2016-09-22

申请号：US14442445

申请日：2013-11-12

Applicant: Biontech AG ,  Ganymed Pharmaceuticals AG ,  TRON-Translationale Onkologie an der Universitatsm edizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Christiane Stadler ,  Julia Holland ,  Hayat Bahr-Mahmud ,  Tim Beissert ,  Laura Plum ,  Fabrice Le Gall ,  Arne Jendretzki ,  Markus Fiedler

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74

Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Abstract translation: 本发明提供含有结合结构域的结合剂，所述结合结构域对于能够结合T细胞的CD3和与肿瘤相关的紧密连接蛋白分子特异性的结合结构域是特异性的，以及使用这些结合剂或其编码的核酸来治疗癌症的方法 。

公开(公告)号：US20160159901A1

公开(公告)日：2016-06-09

申请号：US14904011

申请日：2014-07-30

Applicant: GANYMED PHARMACEUTICALS AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG ,  BIONTECH AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: C07K16/28 ,  A61K33/24 ,  A61K31/7064 ,  A61K31/7048 ,  A61N5/10 ,  C07K16/30 ,  A61K39/395 ,  A61K47/48 ,  G01N33/574 ,  A61K31/337 ,  A61K31/5365

CPC classification number: C07K16/28 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/24 ,  A61K39/39558 ,  A61K47/6851 ,  A61K2039/505 ,  A61N5/10 ,  C07K16/30 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2800/52

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

Abstract translation: 本发明提供了诊断或治疗包括靶向CLDN6的癌症干细胞的癌症疾病的方法。 特别地，本发明提供了一种确定癌症干细胞的方法，包括检测表达CLDN6的细胞。此外，本发明提供了治疗或预防癌症的方法，包括通过施用具有以下能力的抗体来抑制和/或消除癌症干细胞： 与CLDN6结合至癌症患者。

公开(公告)号：US09194004B2

公开(公告)日：2015-11-24

申请号：US13864411

申请日：2013-04-17

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Gerd Helftenbein ,  Dirk Usener ,  Volker Schluter

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: G01N33/57492 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G06F19/22

Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.

公开(公告)号：US20150247206A1

公开(公告)日：2015-09-03

申请号：US14712233

申请日：2015-05-14

Applicant: BioNTech AG ,  Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski

IPC: C12Q1/68 ,  C07K16/40 ,  C07K16/28 ,  G01N33/574 ,  C12N15/113

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  A61K39/39558 ,  A61K47/6807 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1138 ,  C12N15/8218 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/715 ,  G01N2333/7158 ,  G01N2333/916

Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.